ClinicalTrials.gg
CompletedNCT04640311Updated Apr 10, 2025Results posted

Comparison of Daprodustat Formulations Produced by Two Methods of Manufacture for Bioequivalence and Dissolution in Healthy Participants

A Phase 1 interventional study of Daprodustat in Anaemia, sponsored by GlaxoSmithKline. Completed at 4 sites in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-10.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
259
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies testing GSK1278863 in Anemia — 1 open to participants now, 1 under way, 1 of them phase 3. GSK1278863 · Anemia.

Enrollment
7th of 30
259 · median 76
Started
2020
the only one that year
Phase 1
10 of 30
none open now
Registered
27th of 30
by date
Lead sponsor
28 of 30
GlaxoSmithKline

Among the 30 studies testing GSK1278863 in Anemia, this one is the 7th largest by enrollment, is the only one that started in 2020, is one of 10 in phase 1, and was the 27th registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

1 of the 30 studies testing GSK1278863 in Anemia is open now. Recruiting first, the newest first:

About GSK1278863

GSK1278863: first FDA approval 2023 (JESDUVROQ). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing GSK1278863 in Anemia, or all of them as a file.
02

Study summary

This study is comprised of two discrete Parts. Part A is a 3-period cross over evaluating relative bioavailability. Part B is a 2-period cross over evaluating bioequivalence. There will be a minimum of a 7-day washout period between treatment periods. Participants will participate in Part A or Part B, but not both. Approximately 200 participants will be included in the study.

03

Conditions studied

  • Anaemia

Browse trials for

Keywords

  • Daprodustat
  • Pharmacokinetic
  • Bioequivalence
  • Bioavailability
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be 18 to 50 years of age inclusive, at the time of signing the .
  • Participants must be overtly healthy as determined by medical evaluation including medical history, physical examination, and laboratory tests. A participant with a clinical abnormality or laboratory parameter(s) which is/are not specifically listed in the inclusion or exclusion criteria, outside the reference range for the population being studied may be included only if the investigator and/or the Medical Monitor agree and document that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.
  • Participants with body weight more than or equal to (>=) 45 kilogram (kg) and (BMI) within the range 19-31 kg per meter square (Kg/m\^2).
  • Male or female
  • A female participant is eligible to participate if she is not breastfeeding, and at least; not pregnant as confirmed by pregnancy testing or not a woman of (WOCBP) or agrees to follow the guidance during the treatment period to the follow-up visit.
  • Participants capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

Exclusion criteria

Exclusion Criteria:

  • Participants with history of within the prior 2 years or currently receiving treatment for cancer. The only exception is localized squamous- or basal-cell carcinoma of the skin definitively treated 12 weeks or more prior to enrolment.
  • Participants unable to refrain from the use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and Medical Monitor the medication will not interfere with the study procedures or compromise participant safety.
  • Participation in the study would result in loss of blood or blood products in excess of 500 milliliter (mL) within 30 days prior to Day 1 in this study. Exposure to more than 4 new chemical entities within 12 months prior to the first dosing day.
  • Current enrolment or past participation (administration of last dose of study treatment) within the last 30 days (or 5 half-lives, whichever is longer) before Day 1 in this study in any other clinical study involving an investigational study intervention or any other type of medical research.
  • Part A participants may not participate in Part B, and Part B participants may not participate in Part A if enrolment is concurrent or overlaps.
  • Participants with positive pre-study drug/alcohol screen.
  • Participants with regular use of known drugs of abuse.
  • Participants with a positive laboratory confirmation of Coronavirus disease 2019 (COVID-19) infection, or high clinical index of suspicion for COVID-19.
  • Participants with regular alcohol consumption within 6 months prior to the study.
  • Participants with urinary cotinine levels indicative of smoking or history or regular use of tobacco or nicotine containing products (nicotine patches or vaporizing devices) within 6 months prior to screening.
  • Participants with sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the investigator or medical monitor, contraindicates participation in the study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
259 participants (actual)

Study arms

  • Experimental
    Part A: Daprodustat Dissolution 1/Dissolution 2/Reference

    Drug: Daprodustat

  • Experimental
    Part A: Daprodustat Dissolution 2/Reference/Dissolution 1

    Drug: Daprodustat

  • Experimental
    Part A: Daprodustat Reference/Dissolution 1/Dissolution 2

    Drug: Daprodustat

  • Experimental
    Part B: Daprodustat Process 1/ Process 2

    Drug: Daprodustat

  • Experimental
    Part B: Daprodustat Process 2/ Process 1

    Drug: Daprodustat

Interventions

  • Daprodustat will be available as oral tablets.

06

What researchers measure

Primary outcomes

  1. Part A: Area Under the Concentration-time Curve (AUC) From Zero (Pre-dose) to Time of Last Quantifiable Concentration (AUC[0-t]) Following Administration of Daprodustat

    Blood samples were collected at indicated time points to investigate the pharmacokinetics of daprodustat. Pharmacokinetic analysis was conducted using standard non-compartmental methods. The geometric coefficient of variation is model adjusted and is a within-participant coefficient of variation. Analysis was performed using a mixed effect model.

    Time frame: Pre-dose and 30 minutes, 1 Hour, 2 Hours, 2 Hours 30 Minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours Post-dose in Treatment Periods 1, 2 and 3

  2. Part B: AUC(0-t) Following Administration of Daprodustat

    Blood samples were collected at indicated time points to investigate the pharmacokinetics of daprodustat. Pharmacokinetic analysis was conducted using standard non-compartmental methods. The geometric coefficient of variation is model adjusted and is a within-participant coefficient of variation. Analysis was performed using a mixed effect model.

    Time frame: Pre-dose and 30 minutes, 1 Hour, 2 Hours, 2 Hours 30 Minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours Post-dose in Treatment Periods 1 and 2

  3. Part A: Maximum Observed Plasma Concentration (Cmax) Following Administration of Daprodustat

    Blood samples were collected at indicated time points to investigate the pharmacokinetics of daprodustat. Pharmacokinetic analysis was conducted using standard non-compartmental methods. The geometric coefficient of variation is model adjusted and is a within-participant coefficient of variation. Analysis was performed using a mixed effect model.

    Time frame: Pre-dose and 30 minutes, 1 Hour, 2 Hours, 2 Hours 30 Minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours Post-dose in Treatment Periods 1, 2 and 3

  4. Part B: Cmax Following Administration of Daprodustat

    Blood samples were collected at indicated time points to investigate the pharmacokinetics of daprodustat. Pharmacokinetic analysis was conducted using standard non-compartmental methods. The geometric coefficient of variation is model adjusted and is a within-participant coefficient of variation. Analysis was performed using a mixed effect model.

    Time frame: Pre-dose and 30 minutes, 1 Hour, 2 Hours, 2 Hours 30 Minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours Post-dose in Treatment Periods 1 and 2

Secondary outcomes

  1. Part A: AUC From Zero Time (Pre-dose) Extrapolated to Infinite Time (AUC[0-inf]) Following Administration of Daprodustat

    Blood samples were collected at indicated time points to investigate the pharmacokinetics of daprodustat. Pharmacokinetic analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose and 30 minutes, 1 Hour, 2 Hours, 2 Hours 30 Minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours Post-dose in Treatment Periods 1, 2 and 3

  2. Part A: Time of Occurrence of Cmax (Tmax) Following Administration of Daprodustat

    Blood samples were collected at indicated time points to investigate the pharmacokinetics of daprodustat. Pharmacokinetic analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose and 30 minutes, 1 Hour, 2 Hours, 2 Hours 30 Minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours Post-dose in Treatment Periods 1, 2 and 3

  3. Part A: Terminal Phase Half-life (T1/2) Following Administration of Daprodustat

    Blood samples were collected at indicated time points to investigate the pharmacokinetics of daprodustat. Pharmacokinetic analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose and 30 minutes, 1 Hour, 2 Hours, 2 Hours 30 Minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours Post-dose in Treatment Periods 1, 2 and 3

  4. Part A: Apparent Clearance Following Oral Administration of Daprodustat

    Blood samples were collected at indicated time points to investigate the pharmacokinetics of daprodustat. Pharmacokinetic analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose and 30 minutes, 1 Hour, 2 Hours, 2 Hours 30 Minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours Post-dose in Treatment Periods 1, 2 and 3

  5. Part A: Apparent Volume of Distribution Following Oral Administration of Daprodustat

    Blood samples were collected at indicated time points to investigate the pharmacokinetics of daprodustat. Pharmacokinetic analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose and 30 minutes, 1 Hour, 2 Hours, 2 Hours 30 Minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours Post-dose in Treatment Periods 1, 2 and 3

  6. Part B: AUC(0-inf) Following Administration of Daprodustat

    Blood samples were collected at indicated time points to investigate the pharmacokinetics of daprodustat. Pharmacokinetic analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose and 30 minutes, 1 Hour, 2 Hours, 2 Hours 30 Minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours Post-dose in Treatment Periods 1 and 2

  7. Part B: Tmax Following Administration of Daprodustat

    Blood samples were collected at indicated time points to investigate the pharmacokinetics of daprodustat. Pharmacokinetic analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose and 30 minutes, 1 Hour, 2 Hours, 2 Hours 30 Minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours Post-dose in Treatment Periods 1 and 2

  8. Part B: T1/2 Following Administration of Daprodustat

    Blood samples were collected at indicated time points to investigate the pharmacokinetics of daprodustat. Pharmacokinetic analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose and 30 minutes, 1 Hour, 2 Hours, 2 Hours 30 Minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours Post-dose in Treatment Periods 1 and 2

  9. Part B: Apparent Clearance Following Oral Administration of Daprodustat

    Blood samples were collected at indicated time points to investigate the pharmacokinetics of daprodustat. Pharmacokinetic analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose and 30 minutes, 1 Hour, 2 Hours, 2 Hours 30 Minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours Post-dose in Treatment Periods 1 and 2

  10. Part B: Apparent Volume of Distribution Following Oral Administration of Daprodustat

    Blood samples were collected at indicated time points to investigate the pharmacokinetics of daprodustat. Pharmacokinetic analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose and 30 minutes, 1 Hour, 2 Hours, 2 Hours 30 Minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours Post-dose in Treatment Periods 1 and 2

07

Results

Posted Jan 26, 2023

Participant flow

Participants were enrolled across 4 centers in the United States. This study consisted of two parts; Part A (3-period crossover study) and Part B (2-period crossover study).

Part A:Treatment Period 1 (Up to 2 Days)
Participant flow — Part A:Treatment Period 1 (Up to 2 Days)
MilestonePart A: Daprodustat DP 1 Process 2/Daprodustat DP 2 Process 2/Daprodustat Process 1Part A: Daprodustat DP 2 Process 2/ Daprodustat Process 1 / Daprodustat DP 1 Process 2Part A: Daprodustat Process 1 / Daprodustat DP 1 Process 2/ Daprodustat DP 2 Process 2Part B: Daprodustat 1 mg Process 2/ Daprodustat 1 mg Process 1Part B: Daprodustat 1 mg Process 1/Daprodustat 1 mg Process 2Part B: Daprodustat 2 mg Process 2/Daprodustat 2 mg Process 1Part B: Daprodustat 2 mg Process 1/ Daprodustat 2 mg Process 2Part B: Daprodustat 4 mg Process 2/ Daprodustat 4 mg Process 1Part B: Daprodustat 4 mg Process 1/Daprodustat 4 mg Process 2Part B: Daprodustat 6 mg Process 2/Daprodustat 6 mg Process 1Part B: Daprodustat 6 mg Process 1/Daprodustat 6 mg Process 2Part B: Daprodustat 8 mg Process 2/Daprodustat 8 mg Process 1Part B: Daprodustat 8 mg Process 1/Daprodustat 8 mg Process 2
Started1618180000000000
Completed1516180000000000
Not completed1200000000000
Withdrew: Physician decision1000000000000
Withdrew: Protocol violation0100000000000
Withdrew: Withdrawn by sponsor due to impact of inclement weather events0100000000000
Part A: Washout 1 (Up to 7 Days)
Participant flow — Part A: Washout 1 (Up to 7 Days)
MilestonePart A: Daprodustat DP 1 Process 2/Daprodustat DP 2 Process 2/Daprodustat Process 1Part A: Daprodustat DP 2 Process 2/ Daprodustat Process 1 / Daprodustat DP 1 Process 2Part A: Daprodustat Process 1 / Daprodustat DP 1 Process 2/ Daprodustat DP 2 Process 2Part B: Daprodustat 1 mg Process 2/ Daprodustat 1 mg Process 1Part B: Daprodustat 1 mg Process 1/Daprodustat 1 mg Process 2Part B: Daprodustat 2 mg Process 2/Daprodustat 2 mg Process 1Part B: Daprodustat 2 mg Process 1/ Daprodustat 2 mg Process 2Part B: Daprodustat 4 mg Process 2/ Daprodustat 4 mg Process 1Part B: Daprodustat 4 mg Process 1/Daprodustat 4 mg Process 2Part B: Daprodustat 6 mg Process 2/Daprodustat 6 mg Process 1Part B: Daprodustat 6 mg Process 1/Daprodustat 6 mg Process 2Part B: Daprodustat 8 mg Process 2/Daprodustat 8 mg Process 1Part B: Daprodustat 8 mg Process 1/Daprodustat 8 mg Process 2
Started1516180000000000
Completed1516180000000000
Not completed0000000000000
Part A:Treatment Period 2 (Up to 2 Days)
Participant flow — Part A:Treatment Period 2 (Up to 2 Days)
MilestonePart A: Daprodustat DP 1 Process 2/Daprodustat DP 2 Process 2/Daprodustat Process 1Part A: Daprodustat DP 2 Process 2/ Daprodustat Process 1 / Daprodustat DP 1 Process 2Part A: Daprodustat Process 1 / Daprodustat DP 1 Process 2/ Daprodustat DP 2 Process 2Part B: Daprodustat 1 mg Process 2/ Daprodustat 1 mg Process 1Part B: Daprodustat 1 mg Process 1/Daprodustat 1 mg Process 2Part B: Daprodustat 2 mg Process 2/Daprodustat 2 mg Process 1Part B: Daprodustat 2 mg Process 1/ Daprodustat 2 mg Process 2Part B: Daprodustat 4 mg Process 2/ Daprodustat 4 mg Process 1Part B: Daprodustat 4 mg Process 1/Daprodustat 4 mg Process 2Part B: Daprodustat 6 mg Process 2/Daprodustat 6 mg Process 1Part B: Daprodustat 6 mg Process 1/Daprodustat 6 mg Process 2Part B: Daprodustat 8 mg Process 2/Daprodustat 8 mg Process 1Part B: Daprodustat 8 mg Process 1/Daprodustat 8 mg Process 2
Started1516180000000000
Completed1211100000000000
Not completed3580000000000
Withdrew: Withdrawn by sponsor due to impact of inclement weather events3560000000000
Withdrew: Adverse event0020000000000
Part A: Washout 2 (Up to 7 Days)
Participant flow — Part A: Washout 2 (Up to 7 Days)
MilestonePart A: Daprodustat DP 1 Process 2/Daprodustat DP 2 Process 2/Daprodustat Process 1Part A: Daprodustat DP 2 Process 2/ Daprodustat Process 1 / Daprodustat DP 1 Process 2Part A: Daprodustat Process 1 / Daprodustat DP 1 Process 2/ Daprodustat DP 2 Process 2Part B: Daprodustat 1 mg Process 2/ Daprodustat 1 mg Process 1Part B: Daprodustat 1 mg Process 1/Daprodustat 1 mg Process 2Part B: Daprodustat 2 mg Process 2/Daprodustat 2 mg Process 1Part B: Daprodustat 2 mg Process 1/ Daprodustat 2 mg Process 2Part B: Daprodustat 4 mg Process 2/ Daprodustat 4 mg Process 1Part B: Daprodustat 4 mg Process 1/Daprodustat 4 mg Process 2Part B: Daprodustat 6 mg Process 2/Daprodustat 6 mg Process 1Part B: Daprodustat 6 mg Process 1/Daprodustat 6 mg Process 2Part B: Daprodustat 8 mg Process 2/Daprodustat 8 mg Process 1Part B: Daprodustat 8 mg Process 1/Daprodustat 8 mg Process 2
Started1211100000000000
Completed1211100000000000
Not completed0000000000000
Part A:Treatment Period 3 (Up to 2 Days)
Participant flow — Part A:Treatment Period 3 (Up to 2 Days)
MilestonePart A: Daprodustat DP 1 Process 2/Daprodustat DP 2 Process 2/Daprodustat Process 1Part A: Daprodustat DP 2 Process 2/ Daprodustat Process 1 / Daprodustat DP 1 Process 2Part A: Daprodustat Process 1 / Daprodustat DP 1 Process 2/ Daprodustat DP 2 Process 2Part B: Daprodustat 1 mg Process 2/ Daprodustat 1 mg Process 1Part B: Daprodustat 1 mg Process 1/Daprodustat 1 mg Process 2Part B: Daprodustat 2 mg Process 2/Daprodustat 2 mg Process 1Part B: Daprodustat 2 mg Process 1/ Daprodustat 2 mg Process 2Part B: Daprodustat 4 mg Process 2/ Daprodustat 4 mg Process 1Part B: Daprodustat 4 mg Process 1/Daprodustat 4 mg Process 2Part B: Daprodustat 6 mg Process 2/Daprodustat 6 mg Process 1Part B: Daprodustat 6 mg Process 1/Daprodustat 6 mg Process 2Part B: Daprodustat 8 mg Process 2/Daprodustat 8 mg Process 1Part B: Daprodustat 8 mg Process 1/Daprodustat 8 mg Process 2
Started1211100000000000
Completed1211100000000000
Not completed0000000000000
Part B:Treatment Period 1 (Up to 2 Days)
Participant flow — Part B:Treatment Period 1 (Up to 2 Days)
MilestonePart A: Daprodustat DP 1 Process 2/Daprodustat DP 2 Process 2/Daprodustat Process 1Part A: Daprodustat DP 2 Process 2/ Daprodustat Process 1 / Daprodustat DP 1 Process 2Part A: Daprodustat Process 1 / Daprodustat DP 1 Process 2/ Daprodustat DP 2 Process 2Part B: Daprodustat 1 mg Process 2/ Daprodustat 1 mg Process 1Part B: Daprodustat 1 mg Process 1/Daprodustat 1 mg Process 2Part B: Daprodustat 2 mg Process 2/Daprodustat 2 mg Process 1Part B: Daprodustat 2 mg Process 1/ Daprodustat 2 mg Process 2Part B: Daprodustat 4 mg Process 2/ Daprodustat 4 mg Process 1Part B: Daprodustat 4 mg Process 1/Daprodustat 4 mg Process 2Part B: Daprodustat 6 mg Process 2/Daprodustat 6 mg Process 1Part B: Daprodustat 6 mg Process 1/Daprodustat 6 mg Process 2Part B: Daprodustat 8 mg Process 2/Daprodustat 8 mg Process 1Part B: Daprodustat 8 mg Process 1/Daprodustat 8 mg Process 2
Started00021192122212121212020
Completed00020192020211921202020
Not completed0001012020100
Withdrew: Withdrawal by subject0001001000000
Withdrew: Physician decision0000010020000
Withdrew: Adverse event0000001000100
Part B: Washout 1 (Up to 7 Days)
Participant flow — Part B: Washout 1 (Up to 7 Days)
MilestonePart A: Daprodustat DP 1 Process 2/Daprodustat DP 2 Process 2/Daprodustat Process 1Part A: Daprodustat DP 2 Process 2/ Daprodustat Process 1 / Daprodustat DP 1 Process 2Part A: Daprodustat Process 1 / Daprodustat DP 1 Process 2/ Daprodustat DP 2 Process 2Part B: Daprodustat 1 mg Process 2/ Daprodustat 1 mg Process 1Part B: Daprodustat 1 mg Process 1/Daprodustat 1 mg Process 2Part B: Daprodustat 2 mg Process 2/Daprodustat 2 mg Process 1Part B: Daprodustat 2 mg Process 1/ Daprodustat 2 mg Process 2Part B: Daprodustat 4 mg Process 2/ Daprodustat 4 mg Process 1Part B: Daprodustat 4 mg Process 1/Daprodustat 4 mg Process 2Part B: Daprodustat 6 mg Process 2/Daprodustat 6 mg Process 1Part B: Daprodustat 6 mg Process 1/Daprodustat 6 mg Process 2Part B: Daprodustat 8 mg Process 2/Daprodustat 8 mg Process 1Part B: Daprodustat 8 mg Process 1/Daprodustat 8 mg Process 2
Started00020192020211921202020
Completed00020192020211921202020
Not completed0000000000000
Part B: Treatment Period 2(Up to 2 Days)
Participant flow — Part B: Treatment Period 2(Up to 2 Days)
MilestonePart A: Daprodustat DP 1 Process 2/Daprodustat DP 2 Process 2/Daprodustat Process 1Part A: Daprodustat DP 2 Process 2/ Daprodustat Process 1 / Daprodustat DP 1 Process 2Part A: Daprodustat Process 1 / Daprodustat DP 1 Process 2/ Daprodustat DP 2 Process 2Part B: Daprodustat 1 mg Process 2/ Daprodustat 1 mg Process 1Part B: Daprodustat 1 mg Process 1/Daprodustat 1 mg Process 2Part B: Daprodustat 2 mg Process 2/Daprodustat 2 mg Process 1Part B: Daprodustat 2 mg Process 1/ Daprodustat 2 mg Process 2Part B: Daprodustat 4 mg Process 2/ Daprodustat 4 mg Process 1Part B: Daprodustat 4 mg Process 1/Daprodustat 4 mg Process 2Part B: Daprodustat 6 mg Process 2/Daprodustat 6 mg Process 1Part B: Daprodustat 6 mg Process 1/Daprodustat 6 mg Process 2Part B: Daprodustat 8 mg Process 2/Daprodustat 8 mg Process 1Part B: Daprodustat 8 mg Process 1/Daprodustat 8 mg Process 2
Started00020192020211921202020
Completed00020192020211921201920
Not completed0000000000010
Withdrew: Withdrawal by subject0000000000010

Outcome measures

PrimaryPart A: Area Under the Concentration-time Curve (AUC) From Zero (Pre-dose) to Time of Last Quantifiable Concentration (AUC[0-t]) Following Administration of Daprodustat

Blood samples were collected at indicated time points to investigate the pharmacokinetics of daprodustat. Pharmacokinetic analysis was conducted using standard non-compartmental methods. The geometric coefficient of variation is model adjusted and is a within-participant coefficient of variation. Analysis was performed using a mixed effect model.

Time frame:
Pre-dose and 30 minutes, 1 Hour, 2 Hours, 2 Hours 30 Minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours Post-dose in Treatment Periods 1, 2 and 3
Reported as:
Geometric mean · Hours*nanograms per milliliter
Part A: Area Under the Concentration-time Curve (AUC) From Zero (Pre-dose) to Time of Last Quantifiable Concentration (AUC[0-t]) Following Administration of Daprodustat
Hours*nanograms per milliliterPart A: Daprodustat Process 1Part A: Daprodustat Process 2 Dissolution Profile 1Part A: Daprodustat Process 2 Dissolution Profile 2
Part A: Area Under the Concentration-time Curve (AUC) From Zero (Pre-dose) to Time of Last Quantifiable Concentration (AUC[0-t]) Following Administration of Daprodustat155.5 ± 14.7159.9 ± 14.7158.5 ± 14.7
Statistical analysis
  • Part A: Daprodustat Process 1 vs Part A: Daprodustat Process 2 Dissolution Profile 1 · Geometric mean ratio: 1.028 · 90% CI 0.9699 to 1.090Geometric mean ratio of Daprodustat Process 1 to Process 2 Dissolution Profile 1 has been presented.
  • Part A: Daprodustat Process 1 vs Part A: Daprodustat Process 2 Dissolution Profile 2 · Geometric mean ratio: 1.019 · 90% CI 0.9602 to 1.081Geometric mean ratio of Daprodustat Process 1 to Process 2 Dissolution Profile 2 has been presented.
PrimaryPart B: AUC(0-t) Following Administration of Daprodustat

Blood samples were collected at indicated time points to investigate the pharmacokinetics of daprodustat. Pharmacokinetic analysis was conducted using standard non-compartmental methods. The geometric coefficient of variation is model adjusted and is a within-participant coefficient of variation. Analysis was performed using a mixed effect model.

Time frame:
Pre-dose and 30 minutes, 1 Hour, 2 Hours, 2 Hours 30 Minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours Post-dose in Treatment Periods 1 and 2
Reported as:
Geometric mean · Hours*nanograms per milliliter
Part B: AUC(0-t) Following Administration of Daprodustat
Hours*nanograms per milliliterPart B: Daprodustat 1 mg Process 1Part B: Daprodustat 1 mg Process 2Part B: Daprodustat 2 mg Process 1Part B: Daprodustat 2 mg Process 2Part B: Daprodustat 4 mg Process 1Part B: Daprodustat 4 mg Process 2Part B: Daprodustat 6 mg Process 1Part B: Daprodustat 6 mg Process 2Part B: Daprodustat 8 mg Process 1Part B: Daprodustat 8 mg Process 2
Part B: AUC(0-t) Following Administration of Daprodustat36.97 ± 13.538.02 ± 13.583.27 ± 17.079.08 ± 17.0132.9 ± 15.4134.2 ± 15.4249.5 ± 16.3241.5 ± 16.3292.8 ± 16.3278.5 ± 16.3
Statistical analysis
  • Part B: Daprodustat 1 mg Process 1 vs Part B: Daprodustat 1 mg Process 2 · Geometric mean ratio: 1.029 · 90% CI 0.9770 to 1.083Geometric mean ratio of Daprodustat 1 mg Process 2 to Process 1 has been presented.
  • Part B: Daprodustat 2 mg Process 1 vs Part B: Daprodustat 2 mg Process 2 · Geometric mean ratio: 0.9496 · 90% CI 0.8914 to 1.012Geometric mean ratio of Daprodustat 2 mg Process 2 to Process 1 has been presented.
  • Part B: Daprodustat 4 mg Process 1 vs Part B: Daprodustat 4 mg Process 2 · Geometric mean ratio: 1.010 · 90% CI 0.9533 to 1.070Geometric mean ratio of Daprodustat 4 mg Process 2 to Process 1 has been presented.
  • Part B: Daprodustat 6 mg Process 1 vs Part B: Daprodustat 6 mg Process 2 · Geometric mean ratio: 0.9679 · 90% CI 0.9115 to 1.028Geometric mean ratio of Daprodustat 6 mg Process 2 to Process 1 has been presented.
  • Part B: Daprodustat 8 mg Process 1 vs Part B: Daprodustat 8 mg Process 2 · Geometric mean ratio: 0.9511 · 90% CI 0.8948 to 1.011Geometric mean ratio of Daprodustat 8 mg Process 2 to Process 1 has been presented.
PrimaryPart A: Maximum Observed Plasma Concentration (Cmax) Following Administration of Daprodustat

Blood samples were collected at indicated time points to investigate the pharmacokinetics of daprodustat. Pharmacokinetic analysis was conducted using standard non-compartmental methods. The geometric coefficient of variation is model adjusted and is a within-participant coefficient of variation. Analysis was performed using a mixed effect model.

Time frame:
Pre-dose and 30 minutes, 1 Hour, 2 Hours, 2 Hours 30 Minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours Post-dose in Treatment Periods 1, 2 and 3
Reported as:
Geometric mean · Nanograms per milliliter
Part A: Maximum Observed Plasma Concentration (Cmax) Following Administration of Daprodustat
Nanograms per milliliterPart A: Daprodustat Process 1Part A: Daprodustat Process 2 Dissolution Profile 1Part A: Daprodustat Process 2 Dissolution Profile 2
Part A: Maximum Observed Plasma Concentration (Cmax) Following Administration of Daprodustat68.22 ± 28.771.06 ± 28.771.51 ± 28.7
Statistical analysis
  • Part A: Daprodustat Process 1 vs Part A: Daprodustat Process 2 Dissolution Profile 1 · Geometric mean ratio: 1.042 · 90% CI 0.9308 to 1.166Geometric mean ratio of Daprodustat Process 1 to Process 2 Dissolution Profile 1 has been presented.
  • Part A: Daprodustat Process 1 vs Part A: Daprodustat Process 2 Dissolution Profile 2 · Geometric mean ratio: 1.048 · 90% CI 0.9349 to 1.175Geometric mean ratio of Daprodustat Process 1 to Process 2 Dissolution Profile 2 has been presented.
PrimaryPart B: Cmax Following Administration of Daprodustat

Blood samples were collected at indicated time points to investigate the pharmacokinetics of daprodustat. Pharmacokinetic analysis was conducted using standard non-compartmental methods. The geometric coefficient of variation is model adjusted and is a within-participant coefficient of variation. Analysis was performed using a mixed effect model.

Time frame:
Pre-dose and 30 minutes, 1 Hour, 2 Hours, 2 Hours 30 Minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours Post-dose in Treatment Periods 1 and 2
Reported as:
Geometric mean · Nanograms per milliliter
Part B: Cmax Following Administration of Daprodustat
Nanograms per milliliterPart B: Daprodustat 1 mg Process 1Part B: Daprodustat 1 mg Process 2Part B: Daprodustat 2 mg Process 1Part B: Daprodustat 2 mg Process 2Part B: Daprodustat 4 mg Process 1Part B: Daprodustat 4 mg Process 2Part B: Daprodustat 6 mg Process 1Part B: Daprodustat 6 mg Process 2Part B: Daprodustat 8 mg Process 1Part B: Daprodustat 8 mg Process 2
Part B: Cmax Following Administration of Daprodustat17.90 ± 22.217.39 ± 22.239.20 ± 28.835.30 ± 28.862.05 ± 30.960.21 ± 30.9113.4 ± 26.7109.7 ± 26.7139.5 ± 27.6120.0 ± 27.6
Statistical analysis
  • Part B: Daprodustat 1 mg Process 1 vs Part B: Daprodustat 1 mg Process 2 · Geometric mean ratio: 0.9716 · 90% CI 0.8936 to 1.056Geometric mean ratio of Daprodustat 1 mg Process 2 to Process 1 has been presented.
  • Part B: Daprodustat 2 mg Process 1 vs Part B: Daprodustat 2 mg Process 2 · Geometric mean ratio: 0.9006 · 90% CI 0.8107 to 1.000Geometric mean ratio of Daprodustat 2 mg Process 2 to Process 1 has been presented.
  • Part B: Daprodustat 4 mg Process 1 vs Part B: Daprodustat 4 mg Process 2 · Geometric mean ratio: 0.9703 · 90% CI 0.8665 to 1.087Geometric mean ratio of Daprodustat 4 mg Process 2 to Process 1 has been presented.
  • Part B: Daprodustat 6 mg Process 1 vs Part B: Daprodustat 6 mg Process 2 · Geometric mean ratio: 0.9675 · 90% CI 0.8778 to 1.066Geometric mean ratio of Daprodustat 6 mg Process 2 to Process 1 has been presented.
  • Part B: Daprodustat 8 mg Process 1 vs Part B: Daprodustat 8 mg Process 2 · Geometric mean ratio: 0.8606 · 90% CI 0.7770 to 0.9532Geometric mean ratio of Daprodustat 8 mg Process 2 to Process 1 has been presented.
SecondaryPart A: AUC From Zero Time (Pre-dose) Extrapolated to Infinite Time (AUC[0-inf]) Following Administration of Daprodustat

Blood samples were collected at indicated time points to investigate the pharmacokinetics of daprodustat. Pharmacokinetic analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose and 30 minutes, 1 Hour, 2 Hours, 2 Hours 30 Minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours Post-dose in Treatment Periods 1, 2 and 3
Reported as:
Geometric mean · Hours* nanograms per milliliter
Part A: AUC From Zero Time (Pre-dose) Extrapolated to Infinite Time (AUC[0-inf]) Following Administration of Daprodustat
Hours* nanograms per milliliterPart A: Daprodustat Process 1Part A: Daprodustat Process 2 Dissolution Profile 1Part A: Daprodustat Process 2 Dissolution Profile 2
Part A: AUC From Zero Time (Pre-dose) Extrapolated to Infinite Time (AUC[0-inf]) Following Administration of Daprodustat159.9 ± 34.7162.5 ± 31.5161.5 ± 34.7
SecondaryPart A: Time of Occurrence of Cmax (Tmax) Following Administration of Daprodustat

Blood samples were collected at indicated time points to investigate the pharmacokinetics of daprodustat. Pharmacokinetic analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose and 30 minutes, 1 Hour, 2 Hours, 2 Hours 30 Minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours Post-dose in Treatment Periods 1, 2 and 3
Reported as:
Median · Hours
Part A: Time of Occurrence of Cmax (Tmax) Following Administration of Daprodustat
HoursPart A: Daprodustat Process 1Part A: Daprodustat Process 2 Dissolution Profile 1Part A: Daprodustat Process 2 Dissolution Profile 2
Part A: Time of Occurrence of Cmax (Tmax) Following Administration of Daprodustat2.500 (0.500 to 8.00)2.000 (1.00 to 6.00)2.000 (1.00 to 4.00)
SecondaryPart A: Terminal Phase Half-life (T1/2) Following Administration of Daprodustat

Blood samples were collected at indicated time points to investigate the pharmacokinetics of daprodustat. Pharmacokinetic analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose and 30 minutes, 1 Hour, 2 Hours, 2 Hours 30 Minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours Post-dose in Treatment Periods 1, 2 and 3
Reported as:
Geometric mean · Hours
Part A: Terminal Phase Half-life (T1/2) Following Administration of Daprodustat
HoursPart A: Daprodustat Process 1Part A: Daprodustat Process 2 Dissolution Profile 1Part A: Daprodustat Process 2 Dissolution Profile 2
Part A: Terminal Phase Half-life (T1/2) Following Administration of Daprodustat1.797 ± 28.91.910 ± 25.01.932 ± 34.0
SecondaryPart A: Apparent Clearance Following Oral Administration of Daprodustat

Blood samples were collected at indicated time points to investigate the pharmacokinetics of daprodustat. Pharmacokinetic analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose and 30 minutes, 1 Hour, 2 Hours, 2 Hours 30 Minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours Post-dose in Treatment Periods 1, 2 and 3
Reported as:
Geometric mean · Liters per hour
Part A: Apparent Clearance Following Oral Administration of Daprodustat
Liters per hourPart A: Daprodustat Process 1Part A: Daprodustat Process 2 Dissolution Profile 1Part A: Daprodustat Process 2 Dissolution Profile 2
Part A: Apparent Clearance Following Oral Administration of Daprodustat25.02 ± 34.724.61 ± 31.524.77 ± 34.7
SecondaryPart A: Apparent Volume of Distribution Following Oral Administration of Daprodustat

Blood samples were collected at indicated time points to investigate the pharmacokinetics of daprodustat. Pharmacokinetic analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose and 30 minutes, 1 Hour, 2 Hours, 2 Hours 30 Minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours Post-dose in Treatment Periods 1, 2 and 3
Reported as:
Geometric mean · Liters
Part A: Apparent Volume of Distribution Following Oral Administration of Daprodustat
LitersPart A: Daprodustat Process 1Part A: Daprodustat Process 2 Dissolution Profile 1Part A: Daprodustat Process 2 Dissolution Profile 2
Part A: Apparent Volume of Distribution Following Oral Administration of Daprodustat64.87 ± 42.467.81 ± 47.369.05 ± 50.9
SecondaryPart B: AUC(0-inf) Following Administration of Daprodustat

Blood samples were collected at indicated time points to investigate the pharmacokinetics of daprodustat. Pharmacokinetic analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose and 30 minutes, 1 Hour, 2 Hours, 2 Hours 30 Minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours Post-dose in Treatment Periods 1 and 2
Reported as:
Geometric mean · Hours* nanograms per milliliter
Part B: AUC(0-inf) Following Administration of Daprodustat
Hours* nanograms per milliliterPart B: Daprodustat 1 mg Process 1Part B: Daprodustat 1 mg Process 2Part B: Daprodustat 2 mg Process 1Part B: Daprodustat 2 mg Process 2Part B: Daprodustat 4 mg Process 1Part B: Daprodustat 4 mg Process 2Part B: Daprodustat 6 mg Process 1Part B: Daprodustat 6 mg Process 2Part B: Daprodustat 8 mg Process 1Part B: Daprodustat 8 mg Process 2
Part B: AUC(0-inf) Following Administration of Daprodustat37.71 ± 33.138.81 ± 37.884.36 ± 36.078.59 ± 34.1135.5 ± 32.7135.2 ± 33.0250.4 ± 38.7246.0 ± 40.5295.8 ± 38.5282.7 ± 39.3
SecondaryPart B: Tmax Following Administration of Daprodustat

Blood samples were collected at indicated time points to investigate the pharmacokinetics of daprodustat. Pharmacokinetic analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose and 30 minutes, 1 Hour, 2 Hours, 2 Hours 30 Minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours Post-dose in Treatment Periods 1 and 2
Reported as:
Median · Hours
Part B: Tmax Following Administration of Daprodustat
HoursPart B: Daprodustat 1 mg Process 1Part B: Daprodustat 1 mg Process 2Part B: Daprodustat 2 mg Process 1Part B: Daprodustat 2 mg Process 2Part B: Daprodustat 4 mg Process 1Part B: Daprodustat 4 mg Process 2Part B: Daprodustat 6 mg Process 1Part B: Daprodustat 6 mg Process 2Part B: Daprodustat 8 mg Process 1Part B: Daprodustat 8 mg Process 2
Part B: Tmax Following Administration of Daprodustat2.000 (0.500 to 4.00)2.000 (0.517 to 4.00)2.250 (1.00 to 4.00)2.000 (0.500 to 4.00)2.000 (1.00 to 4.00)2.000 (0.500 to 4.00)2.000 (0.500 to 4.00)1.000 (0.500 to 4.00)2.000 (1.00 to 4.00)2.000 (0.500 to 6.00)
SecondaryPart B: T1/2 Following Administration of Daprodustat

Blood samples were collected at indicated time points to investigate the pharmacokinetics of daprodustat. Pharmacokinetic analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose and 30 minutes, 1 Hour, 2 Hours, 2 Hours 30 Minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours Post-dose in Treatment Periods 1 and 2
Reported as:
Geometric mean · Hours
Part B: T1/2 Following Administration of Daprodustat
HoursPart B: Daprodustat 1 mg Process 1Part B: Daprodustat 1 mg Process 2Part B: Daprodustat 2 mg Process 1Part B: Daprodustat 2 mg Process 2Part B: Daprodustat 4 mg Process 1Part B: Daprodustat 4 mg Process 2Part B: Daprodustat 6 mg Process 1Part B: Daprodustat 6 mg Process 2Part B: Daprodustat 8 mg Process 1Part B: Daprodustat 8 mg Process 2
Part B: T1/2 Following Administration of Daprodustat1.162 ± 28.21.163 ± 30.21.545 ± 32.31.489 ± 32.61.814 ± 31.21.775 ± 26.51.852 ± 24.51.920 ± 24.41.997 ± 35.32.136 ± 35.0
SecondaryPart B: Apparent Clearance Following Oral Administration of Daprodustat

Blood samples were collected at indicated time points to investigate the pharmacokinetics of daprodustat. Pharmacokinetic analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose and 30 minutes, 1 Hour, 2 Hours, 2 Hours 30 Minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours Post-dose in Treatment Periods 1 and 2
Reported as:
Geometric mean · Liters per hour
Part B: Apparent Clearance Following Oral Administration of Daprodustat
Liters per hourPart B: Daprodustat 1 mg Process 1Part B: Daprodustat 1 mg Process 2Part B: Daprodustat 2 mg Process 1Part B: Daprodustat 2 mg Process 2Part B: Daprodustat 4 mg Process 1Part B: Daprodustat 4 mg Process 2Part B: Daprodustat 6 mg Process 1Part B: Daprodustat 6 mg Process 2Part B: Daprodustat 8 mg Process 1Part B: Daprodustat 8 mg Process 2
Part B: Apparent Clearance Following Oral Administration of Daprodustat26.52 ± 33.125.76 ± 37.823.71 ± 36.025.45 ± 34.129.53 ± 32.729.58 ± 33.023.96 ± 38.724.39 ± 40.527.04 ± 38.528.30 ± 39.3
SecondaryPart B: Apparent Volume of Distribution Following Oral Administration of Daprodustat

Blood samples were collected at indicated time points to investigate the pharmacokinetics of daprodustat. Pharmacokinetic analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose and 30 minutes, 1 Hour, 2 Hours, 2 Hours 30 Minutes, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours Post-dose in Treatment Periods 1 and 2
Reported as:
Geometric mean · Liters
Part B: Apparent Volume of Distribution Following Oral Administration of Daprodustat
LitersPart B: Daprodustat 1 mg Process 1Part B: Daprodustat 1 mg Process 2Part B: Daprodustat 2 mg Process 1Part B: Daprodustat 2 mg Process 2Part B: Daprodustat 4 mg Process 1Part B: Daprodustat 4 mg Process 2Part B: Daprodustat 6 mg Process 1Part B: Daprodustat 6 mg Process 2Part B: Daprodustat 8 mg Process 1Part B: Daprodustat 8 mg Process 2
Part B: Apparent Volume of Distribution Following Oral Administration of Daprodustat44.45 ± 31.743.22 ± 43.652.83 ± 43.154.65 ± 30.977.28 ± 43.975.74 ± 40.364.02 ± 37.167.56 ± 38.977.92 ± 54.587.21 ± 42.6

Adverse events

Collected over All-cause mortality, serious adverse events (SAEs) and non-serious adverse events (non-SAEs) were collected up to 27 days in Part A and up to 18 days in Part B of the study.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A: Daprodustat Process 10/46 (0%)0/46 (0%)2/46 (4.3%)
Part A: Daprodustat Process 2 Dissolution Profile 10/45 (0%)0/45 (0%)3/45 (6.7%)
Part A: Daprodustat Process 2 Dissolution Profile 20/43 (0%)0/43 (0%)0/43 (0%)
Part B: Daprodustat 1 mg Process 10/39 (0%)0/39 (0%)1/39 (2.6%)
Part B: Daprodustat 1 mg Process 20/40 (0%)0/40 (0%)1/40 (2.5%)
Part B: Daprodustat 2 mg Process 10/42 (0%)0/42 (0%)3/42 (7.1%)
Part B: Daprodustat 2 mg Process 20/41 (0%)0/41 (0%)1/41 (2.4%)
Part B: Daprodustat 4 mg Process 10/42 (0%)1/42 (2.4%)3/42 (7.1%)
Part B: Daprodustat 4 mg Process 20/40 (0%)0/40 (0%)5/40 (12.5%)
Part B: Daprodustat 6 mg Process 10/42 (0%)0/42 (0%)6/42 (14.3%)
Part B: Daprodustat 6 mg Process 20/41 (0%)0/41 (0%)1/41 (2.4%)
Part B: Daprodustat 8 mg Process 10/40 (0%)0/40 (0%)5/40 (12.5%)
Part B: Daprodustat 8 mg Process 20/40 (0%)0/40 (0%)0/40 (0%)
Most frequent serious events
Most frequent serious events
EventPart A: Daprodustat Process 1Part A: Daprodustat Process 2 Dissolution Profile 1Part A: Daprodustat Process 2 Dissolution Profile 2Part B: Daprodustat 1 mg Process 1Part B: Daprodustat 1 mg Process 2Part B: Daprodustat 2 mg Process 1Part B: Daprodustat 2 mg Process 2Part B: Daprodustat 4 mg Process 1Part B: Daprodustat 4 mg Process 2Part B: Daprodustat 6 mg Process 1Part B: Daprodustat 6 mg Process 2Part B: Daprodustat 8 mg Process 1Part B: Daprodustat 8 mg Process 2
Abortion spontaneousPregnancy, puerperium and perinatal conditions0/460/450/430/390/400/420/411/420/400/420/410/400/40
Most frequent other events
Showing 10 of 31
Most frequent other events
EventPart A: Daprodustat Process 1Part A: Daprodustat Process 2 Dissolution Profile 1Part A: Daprodustat Process 2 Dissolution Profile 2Part B: Daprodustat 1 mg Process 1Part B: Daprodustat 1 mg Process 2Part B: Daprodustat 2 mg Process 1Part B: Daprodustat 2 mg Process 2Part B: Daprodustat 4 mg Process 1Part B: Daprodustat 4 mg Process 2Part B: Daprodustat 6 mg Process 1Part B: Daprodustat 6 mg Process 2Part B: Daprodustat 8 mg Process 1Part B: Daprodustat 8 mg Process 2
DyspepsiaGastrointestinal disorders0/460/450/430/390/400/420/410/420/400/420/412/400/40
DizzinessNervous system disorders1/460/450/430/390/400/420/411/420/402/420/410/400/40
HeadacheNervous system disorders0/460/450/430/390/402/421/411/421/400/421/411/400/40
Back painMusculoskeletal and connective tissue disorders0/460/450/430/390/400/420/412/420/400/420/410/400/40
Feeling jitteryGeneral disorders0/460/450/431/390/400/420/410/420/400/420/410/400/40
FallInjury, poisoning and procedural complications0/460/450/430/391/400/420/410/420/400/420/410/400/40
Skin abrasionInjury, poisoning and procedural complications0/460/450/430/391/400/420/410/420/400/420/410/400/40
Blood pressure increasedInvestigations0/460/450/430/391/400/420/410/421/400/420/410/400/40
Soft tissue swellingMusculoskeletal and connective tissue disorders0/460/450/430/391/400/420/410/420/400/420/410/400/40
TremorNervous system disorders0/460/450/430/391/400/420/410/420/400/420/410/400/40

Baseline characteristics

Baseline Characteristics were presented for Safety Population.

Age, Categorical
Age, Categorical(Participants)Part A: Daprodustat DP 1 Process 2/Daprodustat DP 2 Process 2/Daprodustat Process 1Part A: Daprodustat DP 2 Process 2/ Daprodustat Process 1 / Daprodustat DP 1 Process 2Part A: Daprodustat Process 1 / Daprodustat DP 1 Process 2/ Daprodustat DP 2 Process 2Part B: Daprodustat 1 mg Process 2/ Daprodustat 1 mg Process 1Part B: Daprodustat 1 mg Process 1/Daprodustat 1 mg Process 2Part B: Daprodustat 2 mg Process 2/Daprodustat 2 mg Process 1Part B: Daprodustat 2 mg Process 1/ Daprodustat 2 mg Process 2Part B: Daprodustat 4 mg Process 2/ Daprodustat 4 mg Process 1Part B: Daprodustat 4 mg Process 1/Daprodustat 4 mg Process 2Part B: Daprodustat 6 mg Process 2/Daprodustat 6 mg Process 1Part B: Daprodustat 6 mg Process 1/Daprodustat 6 mg Process 2Part B: Daprodustat 8 mg Process 2/Daprodustat 8 mg Process 1Part B: Daprodustat 8 mg Process 1/Daprodustat 8 mg Process 2Total
<=18 years00000000000000
Between 18 and 65 years16181821192122212121212020259
>=65 years00000000000000
Sex: Female, Male
Sex: Female, Male(Participants)Part A: Daprodustat DP 1 Process 2/Daprodustat DP 2 Process 2/Daprodustat Process 1Part A: Daprodustat DP 2 Process 2/ Daprodustat Process 1 / Daprodustat DP 1 Process 2Part A: Daprodustat Process 1 / Daprodustat DP 1 Process 2/ Daprodustat DP 2 Process 2Part B: Daprodustat 1 mg Process 2/ Daprodustat 1 mg Process 1Part B: Daprodustat 1 mg Process 1/Daprodustat 1 mg Process 2Part B: Daprodustat 2 mg Process 2/Daprodustat 2 mg Process 1Part B: Daprodustat 2 mg Process 1/ Daprodustat 2 mg Process 2Part B: Daprodustat 4 mg Process 2/ Daprodustat 4 mg Process 1Part B: Daprodustat 4 mg Process 1/Daprodustat 4 mg Process 2Part B: Daprodustat 6 mg Process 2/Daprodustat 6 mg Process 1Part B: Daprodustat 6 mg Process 1/Daprodustat 6 mg Process 2Part B: Daprodustat 8 mg Process 2/Daprodustat 8 mg Process 1Part B: Daprodustat 8 mg Process 1/Daprodustat 8 mg Process 2Total
Female56887111048645486
Male11121013121012171315171516173
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part A: Daprodustat DP 1 Process 2/Daprodustat DP 2 Process 2/Daprodustat Process 1Part A: Daprodustat DP 2 Process 2/ Daprodustat Process 1 / Daprodustat DP 1 Process 2Part A: Daprodustat Process 1 / Daprodustat DP 1 Process 2/ Daprodustat DP 2 Process 2Part B: Daprodustat 1 mg Process 2/ Daprodustat 1 mg Process 1Part B: Daprodustat 1 mg Process 1/Daprodustat 1 mg Process 2Part B: Daprodustat 2 mg Process 2/Daprodustat 2 mg Process 1Part B: Daprodustat 2 mg Process 1/ Daprodustat 2 mg Process 2Part B: Daprodustat 4 mg Process 2/ Daprodustat 4 mg Process 1Part B: Daprodustat 4 mg Process 1/Daprodustat 4 mg Process 2Part B: Daprodustat 6 mg Process 2/Daprodustat 6 mg Process 1Part B: Daprodustat 6 mg Process 1/Daprodustat 6 mg Process 2Part B: Daprodustat 8 mg Process 2/Daprodustat 8 mg Process 1Part B: Daprodustat 8 mg Process 1/Daprodustat 8 mg Process 2Total
Asian - South East Asian Heritage00110220111009
Black or African American447810991113521217111
Mixed Race01000000110104
Native Hawaiian or Other Pacific Islander10000010100003
White - Arabic/ North African Heritage131221200000012
White - White/ Caucasian/ European Heritage10109835693131473100
American Indian or Alaska Native00000001100002
Asian - Central/ South Asian Heritage00000210000003
Asian - East Asian Heritage00011000002004
Asian - Japanese Heritage00012210012009
Asian - Mixed Race00001000000001
White00000000100001
08

Study locations

4 sites
  • GSK Investigational Site
    Anaheim, California 92801, United States
  • GSK Investigational Site
    Overland Park, Kansas 66212, United States
  • GSK Investigational Site
    Las Vegas, Nevada 89113, United States
  • GSK Investigational Site
    Austin, Texas 78744, United States
09

References and documents

Publications

  • Shaddinger B, Mahar KM, Sprys M, Andrews SM, Chattoraj S, Israni R, Cobitz A. Comparison of Two Manufacturing Processes of Daprodustat for Bioequivalence and Dissolution in Healthy Volunteers: A Randomized Crossover Study. Clin Pharmacol Drug Dev. 2023 Jul;12(7):739-748. doi: 10.1002/cpdd.1257. Epub 2023 May 1. PubMed 37125459 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD is made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2020 to primary completion in May 2021, 5 months.

Results were first posted in Jan 2023, 1 year 8 months after primary completion.

Of 34 industry-sponsored phase 1 interventional studies under Anemia, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 30. This study's 5 months is below that.

Counting every sponsor, half of 48 studies reached it within 12 months; a quarter within 3 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2020
First posted
Nov 23, 2020
StartActual
Dec 18, 2020
Primary completionActual
May 18, 2021
CompletionActual
May 18, 2021
Results first posted
Jan 26, 2023
Last update
Apr 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04640311
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Nov 23, 2020
Start date
Dec 18, 2020
Primary completion
May 18, 2021
Completion
May 18, 2021
Results posted
Jan 26, 2023
Last update
Apr 10, 2025

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GSK1278863

Start the discussion